Management and Outcomes of Isolated Axillary Node Recurrence in Breast Cancer
- 1 September 2006
- journal article
- research article
- Published by American Medical Association (AMA) in Archives of Surgery
- Vol. 141 (9), 867-874
- https://doi.org/10.1001/archsurg.141.9.867
Abstract
Hypothesis Management strategies affect the outcome of axillary recurrence in breast cancer. Design Population-based analysis. Setting Cancer agency breast cancer database. Patients Two hundred twenty women diagnosed with stage 0 through III breast cancer between 1989 and 2003 who subsequently developed an isolated axillary relapse. Main Outcome Measures Overall survival rate and disease-free survival rate according to treatment strategy of the axillary recurrence. Results Among 19 789 women diagnosed with stage 0 through III breast cancer during the study era, 220 had an isolated axillary recurrence (Kaplan-Meier 5-year isolated axillary relapse rate, 1.0%). The median interval between primary breast cancer diagnosis and axillary recurrence was 2.2 years (range,1.8 months to 11.9 years). Median follow-up time after axillary recurrence was 5.4 years. Treatment for the axillary recurrence included lymph node biopsy (47.3%), complete axillary dissection (25.9%), axillary radiation (65.0%), chemotherapy (24.1%), and hormonal therapy (68.2%). The 5-year Kaplan-Meier overall survival rate estimate after axillary recurrence was 49.3% (95% confidence interval, 42.0-56.3). Median survival time from the isolated axillary recurrence was 4.9 years (range, 2.0 months to 15.1 years). Overall (P<.001) and disease-free (P = .006) survival times were highest in those treated with a combination of surgery and radiation. Other factors associated with improved overall survival rate were an interval from diagnosis to relapse greater than 2.5 years (P = .003), no initial axillary radiation (P<.001), asymptomatic presentation of the recurrence (P = .05), and subsequent systemic treatment (P = .02). Conclusions The 5-year isolated axillary recurrence rate of women treated for breast cancer was 1.0%. Multimodality management at the time of recurrence, including axillary surgery, radiation, and systemic therapy, significantly improved overall and disease-free survival.This publication has 16 references indexed in Scilit:
- Long-term prognosis of patients with axillary recurrence after axillary dissection for invasive breast cancerEuropean Journal of Surgical Oncology, 2005
- Outcomes After Localized Axillary Node Recurrence in Breast CancerAnnals of Surgical Oncology, 2003
- Consequences of axillary recurrence after conservative breast surgeryBritish Journal of Surgery, 2002
- Determinants of axillary recurrence after axillary lymph node dissection for invasive breast cancerEuropean Journal of Surgical Oncology, 2001
- Detection, treatment and outcome of axillary recurrence after axillary clearance for invasive breast cancerBritish Journal of Surgery, 2001
- Presentation, management and outcome of axillary recurrence from breast cancerThe American Journal of Surgery, 2000
- Axillary dissection in breast-conserving surgery for stage i and ii breast cancer: a national cancer data base study of patterns of omission and implications for survivalJournal of the American College of Surgeons, 1999
- The Impact of Prophylactic Axillary Node Dissection on Breast Cancer Survival?A Bayesian Meta-AnalysisAnnals of Surgical Oncology, 1999
- Isolated axillary recurrences after conservative treatment of breast cancerEuropean Journal of Cancer, 1996
- Frequency, sites of relapse, and outcome of regional node failures following conservative surgery and radiation for early breast cancerInternational Journal of Radiation Oncology*Biology*Physics, 1989